The U.S. Food and Drug Administration has approved Eli Lilly’s new obesity treatment after late-stage clinical trials showed patients lost an average of 22% of their body weight. The decision marks a major step for a drug class that has drawn intense attention from doctors, patients, and investors alike.

The approval follows phase 3 data that suggested the treatment could offer substantial weight reduction compared with existing options. Lilly has positioned the drug as part of a growing market for obesity care, as more health systems recognize obesity as a chronic disease requiring long-term treatment.

While the results are being hailed as a breakthrough, the real-world impact will depend on access, cost, insurance coverage, and whether patients can tolerate the medication over time. As with other obesity drugs, broader adoption will likely hinge on how safely and effectively it performs outside controlled trials.

The approval adds fresh momentum to a fast-expanding sector of the pharmaceutical industry, where competition is intensifying to develop more effective treatments for weight management and related metabolic conditions.